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The feasibility of combining local heat treatment with whole- body hypothermia in an effort to 
improve therapeutic gain was assessed. Superficial, non perfused phantom tumors were 
fashioned in eight anesthetized mongrel dogs by transplantation of the spleen from the abdomen 
to a subcutaneous site on the hind limb. After pretreatment of the animal with the vasodilator 
hydralazine (0.5 mg/kg, IV) to enhance normal tissue perfusion, the spleen implant was heated 
with a 2450-MHz microwave diathermy apparatus, first with the animal's core body temperature 
in the normal range (39°C) and then after the animal had been packed in ice to reduce core 
temperature to 30°C. Applied power density and temperatures in both the phantom tumor and 
underlying muscle tissue were recorded during brief interruptions of diathermy until steady-state 
temperatures had been achieved. Under normothermic conditions with time-averaged applied 
power of 0.038 W/ml to phantom tumor and 0.014 W/ml to underlying muscle, tumor 
temperature rose to 45.9 ± l.8°C, while muscle temperature remained at 40.5 ± 0.7°C. During 
whole-body hypothermia applied power could be increased to 0.114 W/ml in phantom tumor and 
to 0.025 W/ml in muscle. Muscle temperature rose only to 33.8 ± l.6°C, while that of the 
nonperfused phantom tumor rose to 53.6 ± 4.3°C with systemic hypothermia. These results are in 
agreement with predictions based on the bioheat transfer equation, i.e., heat extraction from well-
perfused normal tissues is greatly augmented by cooling of the arterial blood, allowing greater 
power input to the tumor-bearing region, higher tumor temperatures, and enhanced therapeutic 
gain during local heat treatments of poorly perfused tumor nodules.  
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During local heat therapy for cancer, power is applied to the tumor-bearing region by 
microwaves, radiofrequency current, or high-intensity ultrasound. The goal of such therapy is to 
elevate tumor temperature to cytotoxic levels, while avoiding thermal damage to surrounding 
normal tissues. In addition to technological methods for focusing applied power within the tumor 
[1], there are physiologic methods for accentuating selective temperature elevations in tumor 
tissue during local heating by manipulation of blood flow. In particular, vasodilator drugs can 
selectively increase blood perfusion of normal tissues in hamsters, rats, and dogs without 
increasing blood flow in any of several transplanted tumor types. The augmented perfusion of 
normal tissues allows greater power input to the treatment region and, in turn, higher steady-state 
temperatures in the tumor, without elevation of normal tissue temperatures to damaging levels 
[2. 3]. These effects can be quite dramatic for larger tumor masses, as has been shown both 
theoretically by solution of the bioheat transfer equation [2, 4] and experimentally by Voorhees 
and Babbs [3]. In those experiments, after administration of a vasodilator drug, hydralazine, 
blood perfusion of normal muscle rose approximately three-fold, while blood perfusion of the 
tumor dropped more than four-fold. In turn, central tumor temperature rose from 39°C to 48°C, a 
level 9.5°C greater than that of the underlying muscle. Those experiments show that selective 
heating of tumor tissue to cytotoxic levels is possible when a difference in local blood flow exists 
and that therapeutically useful perfusion differences can be created with vasoactive drugs. 
 
In theory, such perfusion-related temperature differences between tumor tissue and normal tissue 
during local heating can be further exaggerated by reduction of arterial blood temperature, 
because tissue cooling by blood perfusion depends on both local blood flow and the prevailing 
difference between tissue temperature, T, and arterial blood temperature, Ta [5,6]. In particular, 
the temperature difference, T  Ta, between heated tissue and arterial blood multiplies the effects 
of perfusion on heat transfer. 
 
Accordingly, we performed the following series of in vivo experiments to determine, in a tumor 
model, whether whole-body hypothermia in conjunction with the administration of vasodilators 
can permit lethal temperature elevations sufficient to destroy a neoplasm in a single treatment 
session, while safe temperatures are maintained in surrounding normal tissue. For this initial 
study we chose a tumor model system in which blood flow is known to be zero, yet in which 
histologic and cellular structure is similar to that of many neoplasms.  
 
 
MATERIALS AND METHODS  
 
Specifically, we sought to measure temperature differences between a nonperfused spleen 
implant and underlying normal muscle tissues during local microwave therapy. Eight 
anesthetized dogs were pretreated with the vasodilator hydralazine (0.5 mg/kg, IV), to maximize 
perfusion of normal tissues [3]. Local microwave diathermy of the phantom tumors was 
administered, first with each animal's core body temperature at 38.7 ± 0.8°C and then with 




Tumor Models  
 
Autotransplanted sections of spleen with known zero perfusion were used as tumor models. The 
spleen of the experimental animal was exposed by midline laparotomy. Excess blood was 
expressed from the spleen into the venous system by injection of 1 to 5 ml of dilute (l:20,000) 
epinephrine into the splenic artery. This procedure reduced the spleen to a firm mass of tissue 
with a "fish flesh" consistency. Splenectomy was then performed, hemostasis secured, and the 
abdomen closed in layers with continuous silk sutures. The spleen was trimmed to form a discoid 
approximately 5 to 8 cm in diameter and 0.7 to 1.7 cm thick that was inserted into a 
subcutaneous pocket on the left hind limb of the experimental animal (fig. 1), and the wound was 
closed tightly with sutures. This preparation provided an easily created tumor model that was 
certain to have poor blood flow compared with surrounding normal tissues and that was likely to 













Figure 2 One-dimensional computer model of a superficial tumor. 
 
 
Heating Apparatus  
 
Local heating was accomplished by a Burdick Model MW/200 microwave diathermy apparatus 
incorporating a 12 x 18-cm dihedral angle applicator and operating at 2450 MHz (fig. 1). The 
applicator was placed 2 cm from the phantom tumor surface, with a wooden block 2 cm thick 
used to gauge the distance, and angled such that incident radiation was approximately normal to 




Yellow Springs Instruments (YSI) 500 series hypodermic thermistor probes were used to 
measure tissue temperatures during interruption of the microwave diathermy. Probe resistance 
values were converted to temperature by an electronic driver that provided a digital readout of 
temperature to the nearest 0.1°C. This system, in turn, was calibrated against a mercury 




Temperature distributions in phantom tumor and underlying normal tissues were sampled by 
inserting the YSI probes intermittently into preplaced plastic 1-mm microprobes (fig. l) during 
interruption of the microwave diathermy. This intermittent thermometry technique was chosen to 
avoid field-probe interactions, particularly self-heating of the probes [7]. An attempt was made 
to place the microprobes parallel to each other and separated by a distance of 1 cm, such that the 
interface between the phantom tumor and normal tissue would be approximately halfway 
between the probes. (The exact placement of the catheters was subsequently confirmed at 
postmortem examination.) The rise time for the entire thermometry system, with hypodermic 
thermistors surrounded by plastic cannulas, was 3.7 seconds. 
 
Estimates of the spatial average temperature in the central portion of the phantom tumor and in 
underlying muscle approximately 0.6 cm from the tumor edge were made by averaging discrete 
measurements made at three points, 0.5 cm apart, within each microprobe by withdrawing the 
probe in 0.5-cm increments after the readings had stabilized. Recording of three discrete 
temperature values in the same cannula by this method required about 20 seconds. The core body 
temperature of the animal was measured by a YSI probe of larger caliber placed in the esophagus 
at the level of the point of maximal cardiac impulse palpated on the left chest. 
 
Measurement of Applied Power Density 
 
From the bioheat transfer equation [4, 5] it is easy to show that, beginning with a steady-state 
condition in which temperature is constant with time, if the applied power density is suddenly 
changed, the slope of the temperature-time curve, dT/dt, extrapolated back to the time at which 





cP  , where 
 
P = the change in applied power (W/cm
3
),  
 = the tissue density (g/cm
3
),  
c = the tissue-specific heat (J/g-
o
C), and  
dT/dt = the slope of the temperature-time curve (°C/second). 
 








In the present study we used this method to estimate power density in two ways. First, tap water 
models at room temperature were studied according to the method described in the Appendix. 
Second, in animal experiments, applied power was determined from the temperature elevations 
after 60-second periods of heating in each spleen implant and in underlying normal muscle prior 
to sustained microwave heating. Interrupted heating was then begun to achieve a thermal steady 
state. Because sustained heating was interrupted briefly from time to time for temperature 
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measurements, the time-averaged power density at steady state was computed by multiplying the 
initially measured power density by the duty cycle of heating (i.e., fraction of on-time).  
 
Experimental Protocol  
 
Anesthesia was induced with thiopental sodium and maintained with methoxyflurane, nitrous 
oxide, and oxygen inhalation. Each dog was placed in dorsal recumbency on a V-shaped animal 
board. A rubber mat through which either warmed (40°C) or chilled (2°C) water could be 
circulated was placed under the animal. The animal was monitored electrocardiographically (lead 
II), and a catheter was placed in a brachial artery to record arterial blood pressure with a strain-
gauge transducer and stripchart recorder. Laparotomy, splenectomy, and autotransplantation of 
the spleen segment to the left hind limb were then performed. All animals received hydralazine 
(0.5 mg/kg, IV) 15 minutes prior to heating of the spleen implants. The effects of this single dose 
on arterial blood pressure persisted for the duration of the experiment, except in one animal, to 
which a booster dose was given.  
 
Local temperature responses to microwave diathermy were measured, first with core temperature 
maintained at 39°C and then after reduction of core temperature to 30°C by surface cooling. 
Heating was thus continued for at least 35 minutes, or until tissue temperatures had become 
stable. During the normothermic phase of the experiment core temperature was maintained as 
close to 39°C as possible by circulating warm water through the mat. The diathermy apparatus 
was set to deliver 50 percent of maximal power. Power was then applied during successive 
intervals lasting 1 to 2 minutes, between which temperatures were measured and recorded, with 
the aim of bringing normal tissue to a safe, steady-state level of hyperthermia (40°C). By varying 
the lengths of the off-times between heating periods, the time-averaged applied power could be 
titrated to maintain the measured normal tissue temperature as close to 40°C as possible. During 
this normothermic phase of the study, the duty cycle of heating at steady state averaged 40 per 
cent.  
 
Diathermy was then discontinued, and systemic hypothermia was induced by placing ice bags 
over the thorax and abdomen and circulating 2°C water through the rubber mat under the animal. 
This surface cooling technique produced a reduction in systemic (esophageal) temperature of 
approximately 1 °C/10 minutes and required about 90 minutes. When esophageal temperature 
had reached 30°C, response to diathermy was again monitored. During this hypothermic phase 
the diathermy unit was set to deliver 100 per cent of maximal power, and after measurement of 
applied power density, diathermy was applied for intervals of 3 to 5 minutes, between which 
temperatures were measured. Since the time required to measure temperature in both tumor and 
muscle remained less than 1 minute, the effective duty cycle of heating could be increased to 61 
percent. As before, the achievement of steady-state tissue temperatures was monitored for at 
least 45 minutes. This longer time required to achieve steady state is consistent with the greater 




After completion of the hypothermic phase the animal was killed by intravenous injection of 
saturated KCl solution, and postmortem examination of the tumor bed was performed. The 
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position and separation of the cannula tracts were determined by serial sectioning of the phantom 




First, for each time of measurement, the three discrete observations of temperature in the 
phantom tumor and in the underlying normal tissue were averaged. The resultant values were 
plotted as a function of time during the normothermic or hypothermic phase for each animal. To 
combine data from all animals, temperature values were obtained at 5-minute intervals along 
these curves by linear interpolation. The interpolated temperatures at these times were then 
averaged to provide composite heating curves for the population of eight dogs. Finally, the 
steady-state temperatures in phantom tumor and muscle were determined as the average of the 
last three measured temperature values during a diathermy treatment period. Of particular 
interest was the difference in steady-state temperature between tumor and muscle tissue during 
systemic hypothermia as compared with systemic normothermia.  
 
Comparison with Theoretical Calculations  
 
To compare measured temperature differences with those that would be expected on the basis of 
the fundamental physics of heat transfer, we solved the bioheat transfer equation for the 
particular geometry of a slab of tumor tissue underlain by a much thicker slab of muscle tissue 
and irradiated from above by a microwave generator (fig. 2). To solve the bioheat equation for 
the one-dimensional model, a finite difference routine with a mesh size of 500 nodes was 
implemented using standard computational techniques [8, 9]. The values for absorbed power 
were assumed to decay linearly with depth into the tissue and were scaled to reflect the time-
averaged, steady-state power deposition measured in the experiment. A linear, rather than 
exponential, function relating absorbed power density to depth was chosen on the basis of 
measurements made with the particular antenna used in these experiments, as described in the 
Appendix. Values for muscle blood flow in the presence of hydralazine were taken from 
published studies [3]; for the purposes of these computations, it was assumed that these values do 





Figure 3 shows temperature-time profiles in phantom tumor and underlying muscle tissue during 
microwave heating in a representative animal during normothermia (left) and systemic 
hypothermia to 30°C (right). Figure 4 shows mean temperature-time curves (± 1 SD) for the 
population of eight animals derived from interpolated values at 5-minute intervals. Much higher 
steady-state temperature differences between phantom tumor and underlying normal tissue were 
obtained when arterial blood temperature was reduced to 29°C. The mean tumor-muscle 
differences averaged 5.4°C for normothermic and 19.8°C for hypothermic conditions. The 
corresponding temperature gradients (temperature difference/probe separation) were 4.9 ± 







Figure 3 Temperature-time curves for a representative animal during heating: left, 
systemic normothermia (39°C); right, systemic hypothermia (30°C). Squares represent 
temperatures in tumor; circles, temperatures in underlying muscle. 
 
 
Systemic blood cooling allowed safe application of much greater microwave power. The time-
averaged power density at steady state was 0.040 ± 0.13 W/ml for tumor tissue and 0.014 ± 
0.005 W/ml for muscle tissue during normothermia, compared with 0.114 ± 0.049 W/ml for 
tumor tissue and 0.025 ± 0.028 W/ml for muscle tissue during the hypothermic phase. These 
values measured in vivo agreed well with those measured in tap water models with similar power 
settings: 0.04 W/ml at the tumor probe depth and 0.02 W/ml at the muscle probe depth for the 
normothermic power setting; 0.12 W/ml at tumor probe depth and 0.06 W/ml at muscle probe 
depth for the hypothermic power setting. Ventricular fibrillation did not occur during systemic 
hypothermia in any animal. Neither profound hypotension nor profound bradycardia (table 1) 





TABLE 1. Mean Blood Pressure (mm Hg) During Microwave Diathermy  




The observed results are substantially in agreement with theoretical solutions of the bioheat 
equation for a slab of tumor underlain by a much thicker slab of muscle tissue with similar blood 
flow and power levels. The smooth curves shown in figure 5 represent the expected steady-state 
temperature-depth profiles derived from the bioheat equation for the values of power applied in 
this experiment, with the assumption that blood f1ow was zero in the phantom tumor and 60 
ml/minute/100 g in the underlying muscle tissue. Tumor thickness in this simulation was 1.2 cm 
(mean measured thickness). No attempt was made to optimize tumor edge temperature by 
adjusting applied power. The results for the mathematical model (solid curves in fig. 5) are 
substantially in agreement with the experiment results. The dramatic improvement in 
temperature differentials associated with systemic cooling and increased power density is thus 
largely explained on the basis of heat transfer by conduction and perfusion, as embodied in the 
bioheat equation. The dashed line in figure 5 represents the calculated temperature distribution 
that would have been obtained with the same applied power, but with less arterial blood cooling 






Figure 4. Mean temperature-time curves for the population of eight animals during 
heating: left, systemic normothermia (39°C); right, systemic hypothermia (30°C). 
Squares represent temperatures in tumor; circles, temperatures in underlying muscle; 





This study demonstrates that reduced arterial blood temperature, in conjunction with enhanced 
normal tissue perfusion, can substantially improve temperature differentials between 
superficially located, poorly perfused tumors and underlying normal tissues during local heat 
treatments. With combination therapy, including systemic hypothermia and local hyperthermia 
(SH/LH), a majority of the nonperfused tumor tissue can be brought to clearly cytotoxic 
temperatures (>43°C), while normal tissues remain within a clearly safe temperature range 
(<37
o
C). Such enhanced temperature differences represent significant improvements in 
therapeutic gain over conventional hyperthermia therapy. By means of this therapeutic gain, 
either power levels or blood temperature can be adjusted to bring tumor edge temperatures to 
satisfactory, therapeutic levels.  
 
Typically, 42°C is considered the ideal tumor edge temperature; this corresponds to the maximal 
"safe" temperature for normal tissue. An ideal therapeutic temperature distribution can be 
thought of as one in which all intratumoral temperatures are greater than 42°C and all normal 
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tissue temperatures are less than 42°C. Once it becomes possible to obtain large temperature 
differences between tumor and normal tissue, fine tuning of temperature distributions becomes 
possible. For example, in figure 5 (dashed curve) a therapeutic temperature distribution with all 
intratumoral temperatures greater than 42°C is simulated with the same power levels used in our 
experiment by increasing arterial blood temperature slightly. A similarly improved temperature 
distribution could be obtained by increasing total applied power until edge temperature rose to 
42°C. (The former approach may be necessary with the currently available commercial 




Figure 5. Simulation of experimental results with the bioheat equation for the 
geometry shown in figure 2. Curves represent calculated temperature distributions 
within and beneath a nonperfused, superficial tumor, 1.2 cm thick. Shallow solid 
curve, normothermic arterial blood; steep solid curve, hypothermic arterial blood; 
dashed curve, adjustment of arterial blood temperature necessary to bring tumor edge 
temperature to 42°C. Model parameters were similar to those of the animal experiment. 
Normal tissue perfusion is 0.60 ml/minute/g. Power density, P (W/ml), is computed as a 
function of depth, d (cm), according to the expression P = 0.051  0.022d for 
conditions of normothermia and P = 0.153  0.068d for conditions of hypothermia. 
Therapeutic gain, related to the slope of the temperature-depth curves at the tumor 




The mechanism for the enhancement of therapeutic gain during SH/LH therapy is related to the 
fact that overheating of normal tissues sets a practical limit on the power that can be applied 
during treatment of any specific patient. Heat extraction by blood perfusion is related to the 
difference between local tissue and arterial blood temperatures. During systemic hypothermia, 
local tissues can be raised to higher temperature levels relative to the arterial blood, without 
reaching an absolute temperature likely to produce normal tissue damage. Accordingly, heat 
extraction from well-perfused normal tissues is more efficient, while heat extraction from poorly 
perfused tumor tissue is relatively less enhanced. This physical process was predicted for 
spherical tumor models by Oleson et al. [10] in a previous publication and is predicted as well 
for the bilayered slab geometry (fig. 5). 
 
Clinically, Hahn and Kim [11] heated superficial tumor masses that they believed to have 
reduced blood flow. The temperature elevations that they measured in normothermic patients 
using an inductive heating apparatus (roughly 42°C in tumor and 40.5°C in underlying muscle) 
were not unlike those achieved in our phantom tumor models in normothermic animals. 
Additionally, Song et al. [12] and von Ardenne and Kruger [13] showed that greatly decreased 
perfusion of transplanted carcinomas in the rat may occur during the first 24 hours after an initial 
heat treatment as a result of microvascular stasis. A similar decrease in tumor perfusion may be 
produced with pretreatment by vasodilator drugs [3]. 
 
Therefore, we believe that a clinical analog to the present experiment can be created in humans, 
especially during the second and successive heat treatments of superficial tumor nodules or after 
pretreatment with such vasodilator drugs as hydralazine. Since it is well known that patients 
tolerate systemic hypothermia during cardiovascular surgery and other procedures, it is not 
clinically inconceivable that, for patients with superficial tumor masses that are refractory to 
conventional therapy, combination SH/LH treatment similar to that described in this paper may 
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To measure the specific absorption rate (SAR) of microwave power independently as a function 
of depth in an irradiated aqueous medium, such as tissue, we performed experiments with a 
cylindrical beaker of tap water based on the following rationale. For a cylinder of water of cross-
sectional area A and depth h, if microwave radiation is applied from one end of the cylinder, the 
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SAR T . 
 
It is easy to perform an experiment in which PT is measured for various depths, h, by placing the 
microwave applicator a fixed distance (2 cm) under a glass beaker of water at room temperature. 
The water is irradiated from below for a short interval, t; the water is stirred, and the 
temperature rise, T, is measured immediately. Because the water begins at room temperature 









The process is repeated with different depths of fresh water at room temperature, until a curve of 
PT versus depth is created. The slope of this curve, determined graphically and divided by A, is 
the desired function of SAR versus depth. Such measurements of the SAR-depth integral require 
the simplest phantom possible. They avoid the complications of thermal diffusion and 
convection within a phantom and the uncertainty as to location of temperature probes that are 
associated with direct measurements of SAR. They also provide a spatial average value of SAR 
over an area, A, corresponding in size to the treatment area--the desired result in the present 
studies. 
